DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weaver, M. L.
Right arrow Articles by Mangold, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weaver, M. L.
Right arrow Articles by Mangold, J. B.

Vol. 29, Issue 4, 415-421, April 2001

Pharmacokinetics and Metabolism of Nateglinide in Humans

Margaret L. Weaver, Barbara A. Orwig, Lolita C. Rodriguez, Elizabeth D. Graham, Jefferson A. Chin, Michael J. Shapiro, James F. McLeod, and James B. Mangold

Drug Metabolism and Pharmacokinetics, Preclinical Safety (M.L.W., B.A.O., L.C.R., E.D.G., J.B.M.), Clinical Pharmacology, and Clinical Research (J.F.M.), Novartis Institute for Biomedical Research, East Hanover, New Jersey; and Core Technologies (J.A.C., M.J.S.), Novartis Institute for Biomedical Research, Summit, New Jersey

The pharmacokinetics and metabolism of nateglinide were studied in six healthy male subjects receiving a single oral (120 mg) and intravenous (60 mg) dose of [14C]nateglinide in randomized order. Serial blood and complete urine and feces were collected for 120 h post dose. Nateglinide was rapidly (~90%) absorbed, with peak blood and plasma concentrations at ~1 h post dose. The maximal plasma concentrations of radioactivity (6360 ngEq/ml) and nateglinide (5690 ng/ml) were comparable, and plasma radioactivity concentrations were about twice those of blood at all times. Oral bioavailability was 72%, indicating only a modest first-pass effect. After either dose, plasma nateglinide concentrations declined rapidly with elimination half-lives of 1.5 to 1.7 h and plasma clearance of 7.4 l/h. Plasma radioactivity was eliminated more slowly with half-lives of 52 and 35 h in plasma and blood, respectively, after the oral dose. The contribution of this more slowly eliminated component to the AUC0-infinity was minor. Nateglinide was extensively metabolized, with excretion predominantly (84-87%) in urine. Only ~16% of the dose was excreted unchanged in urine after either dosing route. The major metabolites were the result of oxidative modifications of the isopropyl group. Three of these were monohydroxylated, two of which appeared to be diastereoisomers. Additionally, one metabolite with an unsaturation in the isopropyl group and two diol-containing isomers were identified. Glucuronic acid conjugates resulting from direct glucuronidation of the carboxylic acid were also present. The major metabolite in plasma and urine was the result of hydroxylation of the methine carbon of the isopropyl group.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. Scarsi, M. Podvinec, A. Roth, H. Hug, S. Kersten, H. Albrecht, T. Schwede, U. A. Meyer, and C. Rucker
Sulfonylureas and Glinides Exhibit Peroxisome Proliferator-Activated Receptor {gamma} Activity: A Combined Virtual Screening and Biological Assay Approach
Mol. Pharmacol., February 1, 2007; 71(2): 398 - 406.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
D. Devineni, Y. H. Walter, H. T. Smith, J. S. Lee, P. Prasad, and J. F. McLeod
Pharmacokinetics of Nateglinide in Renally Impaired Diabetic Patients
J. Clin. Pharmacol., February 1, 2003; 43(2): 163 - 170.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.